Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745345 | 1.00 | KMT2A (0.43) | KMT2AKCNN4TK1KIF11ADRB2 | |
| SCHEMBL2177218 | 0.84 | ALDH1A1 (0.43) | KMT2AKCNN4TK1KIF11MDM4 | |
| SCHEMBL4519974 | 0.84 | ALDH1A1 (0.43) | KMT2AKCNN4TK1KIF11MDM4 | |
| SCHEMBL4794864 | 0.83 | TK1 (0.45) | KCNN4TK1KIF11LMNACTSK | |
| SCHEMBL23215946 | 0.83 | TK1 (0.45) | KCNN4TK1KIF11LMNACTSK | |
| SCHEMBL23216478 | 0.83 | TK1 (0.45) | KCNN4TK1KIF11LMNACTSK | |
| SCHEMBL31503681 | 0.83 | KIF11 (0.51) | KMT2AKCNN4TK1KIF11 | |
| SCHEMBL29745219 | 0.83 | KMT2A (0.42) | KMT2AKCNN4TK1KIF11MDM4 | |
| SCHEMBL29745562 | 0.83 | KMT2A (0.42) | KMT2AKCNN4TK1KIF11MDM4 | |
| SCHEMBL25713808 | 0.79 | KIF11 (0.51) | KMT2AKIF11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208110-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11963967-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4228685-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4041229-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081973-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143052-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | KMT2A 3861/4885KCNN4 4105/4885TK1 888/4885 |
| US-12208110-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS1, SGMS2 | KMT2A 4728/4885KCNN4 2441/4885TK1 2049/4885 |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | KMT2A 3861/4885KCNN4 4105/4885TK1 888/4885 |
| US-11963967-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | KMT2A 3861/4885KCNN4 4105/4885TK1 888/4885 |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | KMT2A 229/4885KCNN4 53/4885TK1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.